April is National Donate Life Month and all month long the Pulmonary Hypertension Association (PHA) is bringing awareness to transplant recipients, individuals still on the waiting list for a transplant, donors and donor families and registered donors. The awareness month, established in 2003 by Donate Life America, supports organizations nationwide in their efforts to
The Pulmonary Hypertension Association’s (PHA’s) PH Care Centers (PHCC) Program recently accredited five new centers in support of its commitment to promoting quality care practices through PH center accreditation. Interest in PHA’s continuous quality improvement initiative remains high as PH programs seek accreditation as Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP).
Generic treprostinil, the pulmonary arterial hypertension--targeted therapy currently sold as Remodulin®, is now available for individuals using the medication delivered intravenously. Generic treprostinil injection is approved by the U.S. Food and Drug Administration for both intravenous and subcutaneous use. However, generic treprostinil for subcutaneous use is not available at this time due to the
Pathlight, the flagship magazine of the Pulmonary Hypertension Association (PHA), is published quarterly and sent to all PHA members. Don’t miss the many compelling and informative articles in the March 2019 Issue 1 magazine, including: “Game, Set Hatch” Cover story: Angela Hatch, P.A.-C explains how attending a medical course led to her PAH diagnosis
Meet up with Pulmonary Hypertension Association (PHA) staff as we head out across the nation with information and resources to help people living with conditions which may put them at increased risk of developing PH. PHA is committed to doing outreach and education so people with associated conditions know what to look out for,
“I don’t know anything about [my organ donor], but they are MY HERO.” “I would like to start off by saying that I am here today because of one person and I have no idea who they are! I don’t know what age they were, or whether they were a man or
Dear PH Community, In 1994, just three years after the Pulmonary Hypertension Association (PHA) was founded by three patients and a caregiver, PHA held its first International PH Conference. Its goals were simple, but powerful and, in fact, are still key to Conference’s success today – to have patients gain information from experts, help
The Pulmonary Hypertension Association (PHA) just launched its new Clinical Trial Finder that allows individuals to search for research in pulmonary hypertension (PH), so it seems fitting to highlight a paper published in the most recent edition of Advances in Pulmonary Hypertension, “Basic Science and Clinical Trials: Accelerating the Future.” Authors Stephen J. Halliday,
“You were chosen because you are PHighters and PHighters never back down from a PHight.” “Being diagnosed with pulmonary hypertension (PH) does not mean the end of life, rather the beginning of a new one. It doesn’t mean all dreams must go away, but rather those same dreams can be reimagined. Your
A recent study published in BMC Pediatrics shows that reliable, objective, early criteria for inhaled nitric oxide (iNO) treatment response in newborns with hypoxic respiratory failure (HRF) still needs to be established. An estimated two percent of babies born in the U.S. are thought to need help breathing using machines. About 35,000 of these
